0001555794-16-000008.txt : 20160317 0001555794-16-000008.hdr.sgml : 20160317 20160317121437 ACCESSION NUMBER: 0001555794-16-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160315 FILED AS OF DATE: 20160317 DATE AS OF CHANGE: 20160317 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Xie Lan CENTRAL INDEX KEY: 0001555794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 161511851 MAIL ADDRESS: STREET 1: 29F SHANGHAI TIMES SQUARE STREET 2: NO. 93 HUAI HAI ZHONG ROAD CITY: SHANGHAI STATE: F4 ZIP: 200021 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2016-03-15 0 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001555794 Xie Lan 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 0 1 0 0 VP Finance, China CFO Non-Qualified Stock Option (right to buy) 9.12 2016-03-15 4 A 0 28000.0 0.0 A 2026-03-15 Common Stock 28000 28000 D Restricted Stock Unit 2016-03-15 4 A 0 4000.0 0.0 A Common Stock 4000 8000 D Granted under the Issuer's 2015 Equity Incentive Plan. 25% of such shares vest one year from the date of grant and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Vesting for such RSUs will occur 25% on March 15, 2017, 25% on March 15, 2018, 25% on March 15, 2019, and 25% on March 15, 2020, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment. By: /s/ Wilson W. Cheung, Attorney-in-Fact For: Lan Xie 2016-03-17